PER 2.47% 8.3¢ percheron therapeutics limited

On the ratings front, Sarepta has been the subject of a number...

  1. 12,621 Posts.
    lightbulb Created with Sketch. 1271
    On the ratings front, Sarepta has been the subject of a number of recent research reports. In a report released today, JMP analyst Liisa Bayko maintained a Buy rating on SRPT, with a price target of $90, which represents a potential upside of 45% from where the stock is currently trading. Separately, on the same day, RBC’s Simos Simeonidis reiterated a Buy rating on the stock and has a price target of $108.

    We have to be EXCITED...Sarepta was an $8 stock 5 months ago...Just shows how fast a Biotech moves..

    ANP will have its day...
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 28/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 28/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.